Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats

Pharmaceutical Research

Volumn 19, Issue 9, 2002, Pages 1345-1353

  Horikawa, M ^a   Kato, Y ^a,b   Sugiyama, Y ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Biliary excretion; CPT 11; MRP2; Probenecid; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; PROBENECID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIARRHEA; DRUG BILE LEVEL; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; GASTROINTESTINAL TOXICITY; INTESTINE MUCOSA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; BILE; CAMPTOTHECIN; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036744875     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020358910490     Document Type: Article

References (28)

1. T. Andoh, K. Ishii, and Y. Suzuki. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. USA 84:5565-5569 (1987).
2. L. P. Rivory, M. R. Riou, J. Robert, and S. M. Pond. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 52:1103-1111 (1996).
3. R. Atsumi, W. Suzuki, and H. Hakusui. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159-1169 (1991).
4. R. Ohno, K. Okada, T. Masaoka, A. Kuramoto, T. Arima, Y. Yoshida, H. Ariyoshi, M. Ichimaru, Y. Sasaki, M. Oguro, Y. Ito, Y. Morishima, S. Yokomaku, and K. Ota. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1907 (1990).
5. S. Kudoh, M. Fukuoka, N. Masuda, A. Yoshikawa, Y. Kusunoki, K. Mastui, S.-I. Negoro, N. Takifuji, K. Nakagawa, T. Hirashima, T. Yana, and M. Takada. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy of cisplatin. Jpn. J. Cancer Res. 86:406-413 (1995).
6. S. Negoro, M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Mastui, N. Takifuji, S. Kudoh, H. Nitani, and T. Taguchi. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83:1164-1168 (1991).
7. K. Takasuna, Y. Kasai, Y. Kitano, K. Mori, K. Kakihata, M. Hirohashi, and M. Nomura. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia. Pharmacol. Jpn. 105:447-460 (1995).
8. E. Gupta, T. M. Lestingi, R. Mick, J. Ramirez, E. E. Vokes, and J. Ratain. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54:3723-3725 (1994).
9. K. Takasuna, T. Hagiwara, M. Hirohashi, M. Kato, M. Nomura, E. Nagai, T. Yokoi, and T. Kamataki. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56:3752-3757 (1996).
10. K. Takasuna, T. Hagiwara, M. Hirohashi, M. Kato, M. Nomura, E. Nagai, T. Yokoi, and T. Kamataki. Inhibition of intestinal microfiora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother. Pharmacol. 42:280-286 (1998).
11. K. Takasuna, Y. Kasai, Y. Kitano, K. Mori, R. Kobayashi, T. Hagiwara, K. Kakihata, M. Hirohashi, M. Nomura, E. Nagai, and T. Kamataki. Prospective effect of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 86:978-984 (1995).
12. N. Kaneda and T. Yokokura. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50:1721-1725 (1990).
13. F. Lokieo, P. Canal, C. Gay, E. Chatelut, J. P. Armand, H. Roche, R. Bugat, E. Goncalves, and A. Mathieu-Boue. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, urine. Cancer Chemother. Pharmacol. 36:79-82 (1995).
14. F. Ahmed, V. Vya, A. Cornfield, S. Goodin, T. S. Ravikumar, E. Rubin, and E. Gupta. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res. 19:2067-2072 (1999).
15. X.-Y. Chu, Y. Kato, and Y. Sugiyama. Multiplicity of biliary excretion mechanisms of irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57:1934-1938 (1997).
16. X.-Y. Chu, Y. Kato, K. Niinuma, K. Sudo, H. Hakusui, and Y. Sugiyama. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281:304-314 (1997).
17. X.-Y. Chu, Y. Kato, K. Ueda, H. Suzuki, K. Niinuma, C. A. Tyson, V. Weizer, J. E. Dabb, R. Froehlich, C. E. Green, and Y. Sugiyama. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res. 58:5137-5143 (1998).
18. K. Ueda, Y. Kato, K Komatsu, and Y. Sugiyama. Inhibition of the biliary excretion of methotrexate by probenecid in rats: Quantitative prediction of the interaction from in vitro data. J. Pharmacol. Exp. Ther. 297:1036-1043 (2001).
19. B.-M. Emanuelsson, B. Beermann, and L. K. Paalzow. Nonlinear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol. 32:395-401 (1987).
20. M. Saxena and G. B. Henderson. ATP-dependent efflux of 2,4-dinitrophenyl-S-glutathione. J. Biol. Chem. 270:5312-5319 (1995).
21. K. Yachi, Y. Sugiyama, Y. Sawada, T. Iga, Y. Ikeda, and G. Toda, and M. Hanano. Characterization of rose bengal binding to sinusoidal and canalicular plasma membrane from rat liver. Biochim. Biophys. Acta 978:1-7 (1989).
22. H. G. Klemperer. and G.R. Haynes Thymidine kinase in rat liver during development. Biochem. J. 108:541-546 (1968).
23. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer, J. Pharmacobio.-Dyn. 4:879-885 (1981).
24. K. J. Ullrich and G. Rumrich. Luminal transport step of paraaminohippurate (PAH):transport from PAH-loaded proximal tubular cells into the lumen of the rat kidney in vivo. Pflugers. Arch. 433:735-743 (1997).
25. S. Terashita, T. Sawamoto, S. Deguchi, Y. Tokuma, and T. Hata. Sex-dependent and independent renal excretion of nilvadipine metabolites in rat;evidence for a sex-dependent active secretion in kidney. Xenobiotica 25:37-47 (1995).
26. R. Masereeuw, F. G. Russel, and D. S. Miller. Multiple pathways of organic anion secretion in renal proximal tuble revealed confocal microscopy. Am. J. Physiol. 271:F1173-F1179 (1996).
27. J. G. Slatter, P. Su, J. P. Sams, L. J. Schaaf, and L. C. Wienkers. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25:1157-1164 (1997).
28. T. P. Schaub, J. Kartenbeck, J. Konig, H. Spring, J. Dorsam, G. Staehler, S. Storkel, W. F. Thon, and D. Keppler. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 10:1159-1169 (1999).